The Lancet Oncology in conversation with

Cheryl Lai, Senior Editor of The Lancet Oncology, is joined by Dr Jesse Plascak (Division of Cancer Prevention and Control, The Ohio State University) and Dr Marissa Baker (Department of Environmental & Occupational Health Science, University of Washington School of Public Health) to discuss their population-based study analysing cancer mortality rates by sex, cancer type, and occupation type among working-age adults in the USA. Read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00593-5/fulltextTell us what you thought about this episodeContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Dr Andre Pfob (Department of Obstetrics & Gynecology, Heidelberg University Hospital) and Prof Peter Dubsky (Faculty of Health Sciences and Medicine, University of Lucerne) discuss their Review entitled The Lucerne Toolbox 3: digital health and artificial intelligence to optimise the patient journey in early breast cancer—a multidisciplinary consensus.Click here to read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00463-2/fulltextTell us what you thought about this episodeContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Dr Gary Rodin discusses The human crisis in cancer: a Lancet Oncology Commission which identifies a growing imbalance between technological innovation and the human dimensions of cancer care.Click here to read the full Commission: The human crisis in cancer: a Lancet Oncology CommissionAnd comment: Re-establishing human-centred careTell us what you thought about this episodeContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Deputy Editor Ali Landman speaks with Matthias Preusser (Medical University of Vienna, Vienna, Austria) about two reports from the phase 2 TUXEDO-3 trial investigating patritumab deruxtecan (HER3-Dxd) in patients with active brain metastases of breast cancer or non-small-cell lung cancer. Hear about the potential of HER3-targeted antibody-drug conjugates for brain metastases, why recruiting patients with active brain metastases to clinical trials is so important, and where the field is going next.Click here to read the full article: Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of non-small-cell lung cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trialClick here to read the full article: Patritumab deruxtecan (HER3-Dxd) in patients with active brain metastases of breast cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trialTell us what you thought about this episodeContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Smriti Patodia, Senior Editor of The Lancet Oncology, is joined by Dr Andrea Necchi, Associate Professor at the Vita-Salute San Raffaele University, and the Director of Genitourinary Medical Oncology at the San Raffaele Hospital, in Milan, Italy, to discuss his SunRISe4-trial published in our October issue.Effective treatments are needed for patients with muscle-invasive bladder cancer scheduled for radical cystectomy who are ineligible for or decline to receive neoadjuvant cisplatin-based chemotherapy. SunRISe-4 is a randomised, open-label, phase 2 trial being conducted at 109 investigative centres in ten countries worldwide, and aims to evaluate the safety and efficacy of neoadjuvant TAR-200 plus cetrelimab (anti-PD-1) versus cetrelimab monotherapy in this disease setting.They discuss the unique features of the TAR-200 localised sustained delivery system for gemcitabine, the key findings from the SunRISe4-trial trial, and what the future implications of the findings are in terms of better treatment options for patients with bladder cancer.Read the full article:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00358-4/abstract?dgcid=buzzsprout_icw_podcast_September_25_lanoncTell us what you thought about this episodeContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv